首页 | 本学科首页   官方微博 | 高级检索  
检索        

伊立替康联合氟尿嘧啶、亚叶酸钙二线治疗晚期结直肠癌的临床观察
引用本文:曾继泽,ZHOU Hang,刘霄.伊立替康联合氟尿嘧啶、亚叶酸钙二线治疗晚期结直肠癌的临床观察[J].中国药房,2008,19(23):1812-1813.
作者姓名:曾继泽  ZHOU Hang  刘霄
作者单位:曾继泽 (遵义医学院附属医院肿瘤医院二病区,遵义市,563003); ZHOU Hang (遵义医学院附属医院肿瘤医院二病区,遵义市,563003); 刘霄 (遵义医学院附属医院肿瘤医院二病区,遵义市,563003);
摘    要:目的:观察FOLFIRI方案二线治疗晚期结直肠癌的疗效及安全性。方法:28例FOLFOX4化疗失败的患者,改用FOLFIRI方案挽救化疗。结果:完全缓解为0例,部分缓解6例,稳定16例,进展6例,有效率21.4%。不良反应主要为恶心、呕吐、白细胞减少和延迟性腹泻。结论:FOLFIRI方案二线治疗晚期结直肠癌,疗效肯定,不良反应可控制。

关 键 词:伊立替康  氟尿嘧啶  亚叶酸钙  晚期结直肠癌  化学治疗

Clinical Observation of Irinotecan in Combination of Fluorouracil and Calcium Folinate as A Second Line Treatment for Advanced Colorectal Cancer
ZENG Ji-ze,ZHOU Hang,LIU Xiao.Clinical Observation of Irinotecan in Combination of Fluorouracil and Calcium Folinate as A Second Line Treatment for Advanced Colorectal Cancer[J].China Pharmacy,2008,19(23):1812-1813.
Authors:ZENG Ji-ze  ZHOU Hang  LIU Xiao
Abstract:OBJECTIVE:To observe the clinic efficacy and safety of FOLFIRI as a second line treatment for patients with advanced colorectal cancer.METHODS:Twenty-eight patients with advanced colorectal cancer whose disease progressed after first treatment with FOLFOX4 were included to receive the second line treatment with FOLFIRI regimen.RESULTS:Of the total 28 cases,0 had complete response,6 partial response,16 stable disease,6 progressive disease,and the responsive rate was 21.4%.The majority of adverse reaction was nausea,vomiting,leucopenia and tardive diarrhea.CONCLUSION:As a second line therapy,FOLFIRI has a confirmed therapeutic response and tolerable toxicity in patients with advanced colorectal cancer.
Keywords:Irinotecan  Fluorouracil  Calcium folinate  Advanced colorectal cancer  Chemotherapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号